Merck & Co. (MRK) : Tradition Capital Management reduced its stake in Merck & Co. by 3.99% during the most recent quarter end. The investment management company now holds a total of 141,228 shares of Merck & Co. which is valued at $7.6 Million after selling 5,876 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on May 11, 2016.Merck & Co. makes up approximately 2.54% of Tradition Capital Management’s portfolio.
Other Hedge Funds, Including , Focused Wealth Management Inc boosted its stake in MRK in the latest quarter, The investment management firm added 715 additional shares and now holds a total of 7,992 shares of Merck & Co. which is valued at $430,609. Merck & Co. makes up approx 0.24% of Focused Wealth Management Inc’s portfolio.Congress Asset Management Co boosted its stake in MRK in the latest quarter, The investment management firm added 51,900 additional shares and now holds a total of 937,250 shares of Merck & Co. which is valued at $50.5 Million. Merck & Co. makes up approx 1.24% of Congress Asset Management Co’s portfolio.Gabelli Funds reduced its stake in MRK by selling 78,100 shares or 6.82% in the most recent quarter. The Hedge Fund company now holds 1,067,801 shares of MRK which is valued at $57.2 Million. Merck & Co. makes up approx 0.35% of Gabelli Funds’s portfolio.Lehman Financial Resources boosted its stake in MRK in the latest quarter, The investment management firm added 1,000 additional shares and now holds a total of 51,154 shares of Merck & Co. which is valued at $2.7 Million. Merck & Co. makes up approx 1.44% of Lehman Financial Resources’s portfolio.Sonata Capital Group Inc reduced its stake in MRK by selling 198 shares or 1.26% in the most recent quarter. The Hedge Fund company now holds 15,499 shares of MRK which is valued at $849,965. Merck & Co. makes up approx 0.73% of Sonata Capital Group Inc’s portfolio.
Merck & Co. opened for trading at $53.77 and hit $54.77 on the upside on Monday, eventually ending the session at $54.65, with a gain of 1.43% or 0.77 points. The heightened volatility saw the trading volume jump to 66,49,085 shares. Company has a market cap of $151,273 M.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.